ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Current perspectives on natural and pharmacological interventions for combating drug-induced pulmonary toxicity.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced pulmonary toxicity (DIPT) is a serious and often underappreciated complication that can emerge in patients receiving a wide variety of prescribed drugs, from cytotoxic chemotherapy agents and antiarrhythmics to immunomodulatory compounds. Four agents, in particular methotrexate (MTX), cyclophosphamide (CPA), bleomycin (BLM), and amiodarone (AMI) have the most extensive body of evidence documenting their pulmonary adverse effects, with each capable of producing distinct injury patterns that nonetheless share overlapping features. The mechanisms driving DIPT are far from simple; multiple pathways converge to produce the damage, including oxidative stress, dysregulated inflammatory responses, various modes of programmed cell death (apoptosis, pyroptosis, and ferroptosis), and activation of pro-fibrotic cascades most notably TGF-β1/Smad2/3, NF-κB, and the NLRP3 inflammasome. Standard treatment options for early drug withdrawal, corticosteroids, and supportive care are frequently inadequate, and a significant proportion of patients are left with persistent pulmonary fibrosis long after the causative drug has been stopped. This review offers a thorough examination of the epidemiology, risk determinants, pathological features, diagnostic criteria, and molecular underpinnings of DIPT as caused by MTX, CPA, BLM, and AMI. Going further, it assembles a structured, evidence-grounded compilation of the pharmacological and natural agents that have shown protective potential in experimental DIPT models. Four summary tables covering a combined total of 74 protective interventions are presented, detailing experimental designs, induction protocols, and mechanistic targets. The striking range of strategies assessed spanning small-molecule antioxidants and plant-derived polyphenols to repurposed established drugs highlights the growing understanding that DIPT's mechanistic complexity calls for multi-targeted therapeutic solutions. Taken together, this review integrates available preclinical and clinical data into a practical framework for developing rational lung protection strategies against drug-induced injury.
Indexed as
Identifiers
42429832What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.